Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aceragen, Inc.IDRA · Entity 110652 | Senior VP & General Counsel | January 03, 2018 | January 05, 2018 |
| Keenova Therapeutics plcMNKPF · Entity 28960 | EVP & Chief Legal Officer | June 16, 2022 | June 21, 2022 |
| NOVAVAX INCNVAX · Entity 4632 | EVP, Chief Legal Officer | March 02, 2026 | March 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aceragen, Inc.
Report date January 03, 2018 · Filed January 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.24 · Expires 2028-01-03 | Direct | 270,000 |
Reported balance
After 2018-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-03 · Grant · Acquired 270,000 · Balance 270,000 F1: This option was granted under the Company's 2013 Stock Incentive Plan. The options vest with respect to 25% of the underlying shares on the first anniversary of the date of grant and the balance of the underlying shares vest in twelve equal quarterly installments following the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted under the Company's 2013 Stock Incentive Plan. The options vest with respect to 25% of the underlying shares on the first anniversary of the date of grant and the balance of the underlying shares vest in twelve equal quarterly installments following the first anniversary of the date of grant.
Keenova Therapeutics plc
Report date June 16, 2022 · Filed June 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-06-16 transaction · row 1
1 source rowRow 1 · 2022-06-16 · Disposition to issuer · Disposed 32,011 · Balance 0 F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. |
| Employee Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.15 · Expires 2028-02-01 | Direct | 0 |
Reported balance
After 2022-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-16 · Disposition to issuer · Disposed 39,581 · Balance 0 F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. |
| Employee Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.80 · Expires 2028-04-02 | Direct | 0 |
Reported balance
After 2022-06-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-06-16 · Disposition to issuer · Disposed 128,657 · Balance 0 F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. |
| Employee Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.26 · Expires 2029-04-01 | Direct | 0 |
Reported balance
After 2022-06-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-06-16 · Disposition to issuer · Disposed 78,129 · Balance 0 F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code.
F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy.
F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan.
NOVAVAX INC
Report date March 02, 2026 · Filed March 09, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Statutory Stock Option NQSEC Table II · derivative / convertible security · Conversion / exercise price $10.11 · Expires 2036-03-02 | Direct | 152,000 |
Reported balance
After 2026-03-02 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 152,000 · Balance 152,000 F1: This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security as originally reported in Column 8 of Table II of the Reporting Person's Form 4 filed on March 3, 2026. All other information remains unchanged from the March 3, 2026 filing. F2: One quarter (1/4) of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security as originally reported in Column 8 of Table II of the Reporting Person's Form 4 filed on March 3, 2026. All other information remains unchanged from the March 3, 2026 filing.
F2: One quarter (1/4) of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2026 Filed Mar 5, 2026 11:01 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 4,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023715 · tm268076-1_4seq1.xml · derivative · entry 3 Casey Mark J · CIK 0001415297 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2035-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, (the "Plan") vest on each of the first three (3) anniversaries of March 3, 2025, in each case subject to continued employment through such vesting date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 11:01 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 11,378 | $9.49 | $107,977.22 |
DisclosureSEC source: 0001104659-26-023715 · tm268076-1_4seq1.xml · nonDerivative · entry 2 Casey Mark J · CIK 0001415297 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,067 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 11:01 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023715 · tm268076-1_4seq1.xml · nonDerivative · entry 1 Casey Mark J · CIK 0001415297 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 02:33 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantNon-Statutory Stock Opotion NQ · Derivative | 152,000 | $9.09 Strike: $9.09 | $1,381,680.00 |
DisclosureSEC source: 0001104659-26-023069 · tm267953-1_4seq1.xml · derivative · entry 5 Casey Mark J · CIK 0001415297 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,000 Underlying: Common Stock · 152,000 shares Expires 2036-03-02 F4 · derivative.exercise_date: One quarter (1/4) of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 02:33 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 101,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023069 · tm267953-1_4seq1.xml · derivative · entry 4 Casey Mark J · CIK 0001415297 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,000 Underlying: Common Stock · 101,000 shares Expires 2036-03-02 F3 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of March 2, 2026, in each case subject to continued employment through such vesting date. Read SEC document |
| March 02, 2026 Filed Mar 9, 2026 22:09 UTC Amendment | NOVAVAX INC NVAX · Entity 4632 | GrantNon-Statutory Stock Option NQ · Derivative | 152,000 | $0.00 Strike: $10.11 | $0.00 |
DisclosureSEC source: 0001104659-26-025365 · tm268290-3_4aseq1.xml · derivative · entry 1 Casey Mark J · CIK 0001415297 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,000 Underlying: Common Stock · 152,000 shares Expires 2036-03-02 F1 · derivative.exercise_price: This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security as originally reported in Column 8 of Table II of the Reporting Person's Form 4 filed on March 3, 2026. All other information remains unchanged from the March 3, 2026 filing. F1 · price: This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security as originally reported in Column 8 of Table II of the Reporting Person's Form 4 filed on March 3, 2026. All other information remains unchanged from the March 3, 2026 filing. F2 · derivative.exercise_date: One quarter (1/4) of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 02:33 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 4,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023069 · tm267953-1_4seq1.xml · derivative · entry 3 Casey Mark J · CIK 0001415297 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2034-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, (the "Plan") vest on each of the first three (3) anniversaries of March 1, 2024, in each case subject to continued employment through such vesting date. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 02:33 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 1,214 | $10.14 | $12,309.96 |
DisclosureSEC source: 0001104659-26-023069 · tm267953-1_4seq1.xml · nonDerivative · entry 2 Casey Mark J · CIK 0001415297 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,945 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 02:33 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023069 · tm267953-1_4seq1.xml · nonDerivative · entry 1 Casey Mark J · CIK 0001415297 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 21:01 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 41,899 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-121103 · tm2533544-1_4seq1.xml · derivative · entry 3 Casey Mark J · CIK 0001415297 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,899 Underlying: Common Stock · 41,899 shares Expires 2033-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 21:01 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 12,713 | $6.69 | $85,049.97 |
DisclosureSEC source: 0001104659-25-121103 · tm2533544-1_4seq1.xml · nonDerivative · entry 2 Casey Mark J · CIK 0001415297 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,159 Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 21:01 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 41,899 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-121103 · tm2533544-1_4seq1.xml · nonDerivative · entry 1 Casey Mark J · CIK 0001415297 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:07 UTC | NOVAVAX INC NVAX · Entity 4632 | Grant2025 Restricted Stock Units RSU · Derivative | 112,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000306 · primary_01.xml · derivative · entry 2 Casey Mark J · CIK 0001415297 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2035-03-03 F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:07 UTC | NOVAVAX INC NVAX · Entity 4632 | Grant2025 Non-statutory Stock Option NQ · Derivative | 169,000 | $7.87 Strike: $7.87 | $1,330,030.00 |
DisclosureSEC source: 0001593968-25-000306 · primary_01.xml · derivative · entry 1 Casey Mark J · CIK 0001415297 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,000 Underlying: Common Stock · 169,000 shares Expires 2035-03-03 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 23:46 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 4,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000288 · primary_01.xml · derivative · entry 3 Casey Mark J · CIK 0001415297 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 4,000 shares Expires 2034-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 23:46 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 1,214 | $8.33 | $10,112.62 |
DisclosureSEC source: 0001593968-25-000288 · primary_01.xml · nonDerivative · entry 2 Casey Mark J · CIK 0001415297 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,973 Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 23:46 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000288 · primary_01.xml · nonDerivative · entry 1 Casey Mark J · CIK 0001415297 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 22:24 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 41,900 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-24-001472 · primary_01.xml · derivative · entry 3 Casey Mark J · CIK 0001415297 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,798 Underlying: Common Stock · 41,900 shares Expires 2033-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 22:24 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 12,713 | $8.82 | $112,128.66 |
DisclosureSEC source: 0001593968-24-001472 · primary_01.xml · nonDerivative · entry 2 Casey Mark J · CIK 0001415297 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,187 Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 22:24 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 41,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-24-001472 · primary_01.xml · nonDerivative · entry 1 Casey Mark J · CIK 0001415297 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2024 Filed Mar 26, 2024 23:00 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-039161 · tm249879-1_4seq1.xml · derivative · entry 1 Casey Mark J · CIK 0001415297 · EVP, CLO & Corporate Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the March 1, 2024 grant date, in each case subject to continued employment through such vesting date. F2 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the March 1, 2024 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 22:00 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 125,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-058519 · doc4.xml · derivative · entry 2 Casey Mark J · CIK 0001415297 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,698 Underlying: Common Stock · 125,698 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock. F3 · derivative.exercise_date: The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date. F3 · derivative.expiration_date: The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 22:00 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Options (Right to buy) · Derivative | 144,694 | $0.00 Strike: $5.57 | $0.00 |
DisclosureSEC source: 0001209191-23-058519 · doc4.xml · derivative · entry 1 Casey Mark J · CIK 0001415297 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,694 Underlying: Common Stock · 144,694 shares Expires 2033-12-11 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on the first anniversary of the December 11, 2023 grant date (the "Grant Date"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 18:12 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | Disposition to issuerEmployee Share Options (Right to Buy) · Derivative | 78,129 | $0.00 Strike: $22.26 | $0.00 |
DisclosureSEC source: 0000899243-22-023430 · doc4.xml · derivative · entry 4 Casey Mark J · CIK 0001415297 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 78,129 shares Expires 2029-04-01 F1 · kind: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2 · kind: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3 · kind: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 18:12 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | Disposition to issuerEmployee Share Options (Right to Buy) · Derivative | 128,657 | $0.00 Strike: $13.80 | $0.00 |
DisclosureSEC source: 0000899243-22-023430 · doc4.xml · derivative · entry 3 Casey Mark J · CIK 0001415297 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 128,657 shares Expires 2028-04-02 F1 · kind: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2 · kind: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3 · kind: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 18:12 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | Disposition to issuerEmployee Share Options (Right to Buy) · Derivative | 39,581 | $0.00 Strike: $18.15 | $0.00 |
DisclosureSEC source: 0000899243-22-023430 · doc4.xml · derivative · entry 2 Casey Mark J · CIK 0001415297 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 39,581 shares Expires 2028-02-01 F1 · kind: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2 · kind: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3 · kind: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 18:12 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | Disposition to issuerOrdinary Shares | 32,011 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-023430 · doc4.xml · nonDerivative · entry 1 Casey Mark J · CIK 0001415297 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2 · kind: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3 · kind: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 07:39 UTC | Keenova Therapeutics plc MNKKQ · Entity 28960 | SaleOrdinary Shares | 15,291 | $0.45 | $6,880.95 |
DisclosureSEC source: 0000950138-20-000533 · edgar.xml · nonDerivative · entry 1 Casey Mark J · CIK 0001415297 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,011 Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 16:19 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 2,110 | $1.80 | $3,798.00 |
DisclosureSEC source: 0000950138-20-000198 · edgar.xml · nonDerivative · entry 2 Casey Mark J · CIK 0001415297 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,302 Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 16:19 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 1,462 | $1.93 | $2,821.66 |
DisclosureSEC source: 0000950138-20-000198 · edgar.xml · nonDerivative · entry 1 Casey Mark J · CIK 0001415297 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,412 Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 16:06 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 1,252 | $4.59 | $5,746.68 |
DisclosureSEC source: 0000950138-20-000049 · edgar.xml · nonDerivative · entry 1 Casey Mark J · CIK 0001415297 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,874 Read SEC document |
| April 02, 2019 Filed Apr 3, 2019 18:04 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 2,110 | $22.80 | $48,108.00 |
DisclosureSEC source: 0000950138-19-000229 · edgar.xml · nonDerivative · entry 2 Casey Mark J · CIK 0001415297 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,126 Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:04 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantEmployee Share Options (Right to Buy) · Derivative | 78,129 | $0.00 Strike: $22.62 | $0.00 |
DisclosureSEC source: 0000950138-19-000229 · edgar.xml · derivative · entry 3 Casey Mark J · CIK 0001415297 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,129 Underlying: Ordinary Shares · 78,129 shares Expires 2029-04-01 F2 · derivative.exercise_date: The options vest in four equal annual installments beginning April 1, 2020. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:04 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 17,071 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000229 · edgar.xml · nonDerivative · entry 1 Casey Mark J · CIK 0001415297 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,236 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning April 1, 2020. Read SEC document |
| April 01, 2019 Filed Apr 5, 2019 16:14 UTC Amendment | Keenova Therapeutics plc MNK · Entity 28960 | GrantEmployee Share Options (Right to Buy) · Derivative | 78,129 | $0.00 Strike: $22.26 | $0.00 |
DisclosureSEC source: 0000950138-19-000237 · edgar.xml · derivative · entry 1 Casey Mark J · CIK 0001415297 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,129 Underlying: Ordinary Shares · 78,129 shares Expires 2029-04-01 F1 · derivative.exercise_price: This amended Form 4 is being filed to correct a typographical error in the exercise price of the options which was previously reported as $22.62. F2 · derivative.exercise_date: The options vest in four equal annual installments beginning April 1, 2020. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 07:59 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 1,248 | $22.34 | $27,880.32 |
DisclosureSEC source: 0000950138-19-000060 · edgar.xml · nonDerivative · entry 1 Casey Mark J · CIK 0001415297 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,165 Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 18:13 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantEmployee Share Options (Right to Buy) · Derivative | 128,657 | $0.00 Strike: $13.80 | $0.00 |
DisclosureSEC source: 0000950138-18-000315 · edgar.xml · derivative · entry 2 Casey Mark J · CIK 0001415297 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,657 Underlying: Ordinary Shares · 128,657 shares Expires 2028-04-02 F2 · derivative.exercise_date: The options vest in four equal annual installments beginning April 2, 2019. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 18:13 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 24,638 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000315 · edgar.xml · nonDerivative · entry 1 Casey Mark J · CIK 0001415297 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,413 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning April 2, 2019. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 17:02 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantEmployee Share Options (Right to Buy) · Derivative | 39,581 | $0.00 Strike: $18.15 | $0.00 |
DisclosureSEC source: 0000950138-18-000113 · edgar.xml · derivative · entry 2 Casey Mark J · CIK 0001415297 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,581 Underlying: Ordinary Shares · 39,581 shares Expires 2028-02-01 F2 · derivative.exercise_date: The options vest in four equal annual installments beginning February 1, 2019. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 17:02 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 13,775 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000113 · edgar.xml · nonDerivative · entry 1 Casey Mark J · CIK 0001415297 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,775 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning February 1, 2019. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 16:19 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option · Derivative | 270,000 | $2.24 Strike: $2.24 | $604,800.00 |
DisclosureSEC source: 0001179110-18-000586 · edgar.xml · derivative · entry 1 Casey Mark J · CIK 0001415297 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 270,000 shares Expires 2028-01-03 F1 · derivative.exercise_date: This option was granted under the Company's 2013 Stock Incentive Plan. The options vest with respect to 25% of the underlying shares on the first anniversary of the date of grant and the balance of the underlying shares vest in twelve equal quarterly installments following the first anniversary of the date of grant. Read SEC document |
| January 03, 2017 Filed Jan 6, 2017 16:24 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option · Derivative | 185,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001179110-17-000645 · edgar.xml · derivative · entry 1 Casey Mark J · CIK 0001415297 · Senior VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2027-01-03 F1 · derivative.exercise_date: This option was granted under the Company's 2013 Stock Incentive Plan. The options vest with respect to 25% of the underlying shares on the first anniversary of the date of grant and the balance of the underlying shares vest in twelve equal quarterly installments following the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.